The success of antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PD-1), or PD-L1 in stimulating immune cell mediated tumor rejection suggests that the immune system is poised for exploitation as a therapeutic target [66]. Here, CD274 is linked to neoplasm.